Equity Details
Price & Market Data
Price: $0.56
Daily Change: -$0.0204 / 3.64%
Daily Range: $0.56 - $0.597
Market Cap: $3,860,797
Daily Volume: 62,309
Performance Metrics
1 Week: -0.85%
1 Month: -23.02%
3 Months: -12.78%
6 Months: -51.45%
1 Year: -54.30%
YTD: -22.05%
About Galmed Pharmaceuticals Ltd. (GLMD)
Comprehensive market data and analysis for Galmed Pharmaceuticals Ltd. (GLMD). Current price: 0.56, daily change: -$0.0204 / 3.64%. Market cap: 3,860,797. View detailed YTD, 1-week, and 1-month performance.
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.